Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4989051 | 0.91 | TP53 (0.52) | TRPV1ALOX5APCNR1CNR2MAPT | |
| SCHEMBL2982417 | 0.86 | ALOX5AP (0.53) | ALOX5APCNR1CNR2HDAC6MAPK14 | |
| SCHEMBL2983815 | 0.86 | ALOX5AP (0.52) | ALOX5APCNR1CNR2MAPTHDAC6 | |
| SCHEMBL2977156 | 0.85 | CNR2 (0.54) | ALOX5APCNR1CNR2MAPTHDAC6 | |
| SCHEMBL2985069 | 0.84 | CNR2 (0.56) | ALOX5APCNR1CNR2HDAC6 | |
| SCHEMBL2987507 | 0.84 | CNR2 (0.56) | ALOX5APCNR1CNR2HDAC6 | |
| SCHEMBL2976559 | 0.83 | ALOX5AP (0.52) | ALOX5APCNR1CNR2MAPTHDAC6 | |
| SCHEMBL5286848 | 0.83 | ALOX5AP (0.49) | ALOX5APCNR1CNR2MAPTHDAC6 | |
| SCHEMBL2981649 | 0.83 | EPHX2 (0.53) | ALOX5APHDAC6PPARG | |
| SCHEMBL2981592 | 0.82 | ALOX5AP (0.52) | ALOX5APMAPTHDAC6TP53PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384945-B2 | Indole or benzimidazole derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20060089367-A1 | New indole or benzimidazole derivatives as CB1 inverse agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089367-A1 | New indole or benzimidazole derivatives as CB1 inverse agonists | CNR1, CNR2, GPR119 | TRPV1 11/4885ALOX5AP 910/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.